Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June:

• 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m. ET
• Goldman Sachs 47^th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.

Contact:
Mitch Maisel
[email protected]

Media:
Dan Budwick
1AB
973-271-6085
[email protected]

You May Also Be Interested In

• FirstCash to Acquire Ramsdens, a Leading Pawn, Retail and Financial Services Operator in the United Kingdom
• Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
• Aalberts reports the progress of its share buyback programme 15 June – 19 June 2026